e-learning
resources
Milan 2017
Sunday, 10.09.2017
The spectrum of CTDs: from pathogenesis to treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Rituximab improves interstitial lung disease in rheumatoid arthritis patients
M. Nieto Barbero (Madrid, Spain)
Source:
International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Session:
The spectrum of CTDs: from pathogenesis to treatment
Session type:
Thematic Poster
Number:
893
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Nieto Barbero (Madrid, Spain). Rituximab improves interstitial lung disease in rheumatoid arthritis patients. 893
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis
Source: Eur Respir J 2002; 20: Suppl. 38, 587s
Year: 2002
Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis
Source: Annual Congress 2004 - Fibrosing lung diseases
Year: 2004
Methotrexate and rheumatoid arthritis associated interstitial lung disease
Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020
Year: 2021
Interstitial lung disease in patients with rheumatoid arthritis
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008
Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis
Source: Eur Respir J 2004; 24 : 708
Year: 2004
Predicting outcomes in rheumatoid arthritis related interstitial lung disease
Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018
Year: 2019
Mortality and clinical features in rheumatoid arthritis and interstitial lung disease
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA)
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020
The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management
Year: 2018
Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020
Year: 2021
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2016; 47: 588-596
Year: 2016
Pulmonary involvement in patients with rheumatoid arthritis
Source: Eur Respir J 2006; 28: Suppl. 50, 381s
Year: 2006
Risk factors of interstitial lung diseases in patients with rheumatoid arthritis.
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients
Source: Eur Respir J 2014; 44: 1082-1085
Year: 2014
Pulmonary disease associated with rheumatoid arthritis
Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Year: 2021
Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019
Cavitary nodules in rheumatoid arthritis patients and their prognosis
Source: International Congress 2018 – Sarcoidosis, interstitial lung diseases and various clinical problems
Year: 2018
Analysis of lung diseases associated with rheumatoid arthritis
Source: Eur Respir J 2006; 28: Suppl. 50, 307s
Year: 2006
Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2010; 35: 1206-1208
Year: 2010
The lung in rheumatoid arthritis: drugs versus underlying disease
Source: Annual Congress 2009 - Lung disease in rheumatoid arthritis treated with tumour necrosis factor inhibitors: a pulmonary perspective
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept